65051-17-4

Usage

Uses

Used in Pharmaceutical Research:
N-(3,4-Dichlorophenyl)glycine is used as a research tool for studying the glutamate receptor system and its role in neurological disorders. It acts as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, which is important for synaptic plasticity and memory formation in the brain.
Used in Neuroscience Applications:
In the field of neuroscience, N-(3,4-Dichlorophenyl)glycine is used to investigate the mechanisms of synaptic plasticity and memory formation, as well as the potential therapeutic effects of modulating NMDA receptor activity in various neurological conditions.

InChI:InChI=1/C8H7Cl2NO2/c9-6-2-1-5(3-7(6)10)11-4-8(12)13/h1-3,11H,4H2,(H,12,13)

Upstream product

• 28363-22-6 <(3,4-dichlorophenyl)amino>acetonitrile 
• 79-11-8 chloroacetic acid 
• 95-76-1 m,p-dichloroaniline 
• 50-00-0 formaldehyd 
• 151-50-8 potassium cyanide 
• 14108-81-7 ethyl 2-((3,4-dichlorophenyl)amino)acetate 

Downstream Products

• 132649-63-9 N-[(4-chloro-phenoxy)-acetyl]-N-(3,4-dichloro-phenyl)-glycine 
• 14108-81-7 ethyl 2-((3,4-dichlorophenyl)amino)acetate 
• 92126-17-5 1-(3,4-dichlorophenyl)-3,4-bis(hydroxymethyl)pyrazole bis(methylcarbamate) 
• 92126-14-2 dimethyl 1-(3,4-dichlorophenyl)pyrazole-3,4-dicarboxylate 
• 92126-16-4 1-(3,4-dichlorophenyl)-3,4-bis(hydroxymethyl)pyrazole 
• 92126-15-3 N-nitroso-N-(3,4-dichlorophenyl)glycine 

Relevant academic research and scientific papers

Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage

So far, there is still no specific drug against COVID-19. Taking compound 1 with anti-EBOV activity as the lead, fifty-four 12N-substituted aloperine derivatives were synthesized and evaluated for the anti-SARS-CoV-2 activities using pseudotyped virus model. Among them, 8a exhibited the most potential effects against both pseudotyped and authentic SARS-CoV-2, as well as SARS-CoV and MERS-CoV, indicating a broad-spectrum anti-coronavirus profile. The mechanism study disclosed that 8a might block a late stage of viral entry, mainly via inhibiting host cathepsin B activity rather than directly targeting cathepsin B protein. Also, 8a could significantly reduce the release of multiple inflammatory cytokines in a time- and dose-dependent manner, such as IL-6, IL-1β, IL-8 and MCP-1, the major contributors to cytokine storm. Therefore, 8a is a promising agent with the advantages of broad-spectrum anti-coronavirus and anti-cytokine effects, thus worthy of further investigation.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.

Acetohydroxamic acids

The invention provides new acetohydroxamic acid derivatives, having interesting properties on the central nervous system, of the formula: R1 R2 R3 C-CO-NHOH, in which R2 and R3 are each hydrogen or C1-6 alkyl, and R1 is C1-6 alkyl Z1 Z2 N (where Z1 and Z2 are each phenyl, substituted phenyl, or cycloalkyl), substituted hydantoinyl, benzhydroxylcarboxamido, Z3 CH2 -- (where Z3 = optionally substituted aryl), Z4 -A- (where Z4 is optionally substituted phenyl or naphthyl, and A is --NH--, --N(C1-4 alkyl)--, --N(C5-6 cycloalkyl)--, --NHCO--, --N(C1-4 alkyl)CO--, --N(C5-6 cycloalkyl)CO--, --CONH--, --CON(C1-4 alkyl)--, --CON(C5-6 cycloalkyl)--, --NHCONH--, --N(C5 H6)CONH--, or --N(substituted phenyl)CONH--, optionally substituted benzimidazolyl, or an optionally substituted tricyclic radical, and their metal and acid addition salts.